Nano HoldingsTSE:4571 43 EBITDA Margin % is -650.35% as of Mar. 2026. GuruFocus rates TSE:4571 with a GF Score™ of 43/100 and a GF Value™ of 円187.93 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 936 Biotechnology companies, Nano Holdings ranks worse than 71.9% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nano Holdings's EBITDA for the
three
months ended in Mar. 2026 was 円-283.3 Mil. Nano Holdings's Revenue for the
three
months ended in Mar. 2026 was 円43.6 Mil. Therefore, Nano Holdings's EBITDA margin for the quarter that ended in Mar. 2026 was -650.35%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nano Holdings EBITDA Margin % Related Terms
Nano Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Nano Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4571 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Nano Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nano Holdings EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nano Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nano Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nano Holdings (TSE:4571) has a EBITDA Margin % of -650.35% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nano Holdings and its competitors. According to the industry distribution chart, Nano Holdings ranks #673 out of 936 companies in the Biotechnology industry, placing it in the top 71.9%.
Is Nano Holdings' EBITDA Margin % too high?
Nano Holdings' current EBITDA Margin % is -650.35%. Based on the distribution chart, Nano Holdings ranks #673 out of 936 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nano Holdings has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nano Holdings' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nano Holdings ranks #673 out of 936 companies for EBITDA Margin %. This places Nano Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nano Holdings and its competitors. Nano Holdings's current EBITDA Margin % is -650.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nano Holdings stock overvalued right now?
Based on GuruFocus' analysis, Nano Holdings (TSE:4571) is currently considered Possible Value Trap. The stock's GF Value™ is 円187.93, compared to a current price of 円102.00 — trading 45.7% below its estimated fair value. The current EBITDA Margin % is -650.35%. Nano Holdings' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nano Holdings (TSE:4571), the current EBITDA Margin % is -650.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nano Holdings (TSE:4571) Overvalued in 2026?
Based on GuruFocus' analysis, Nano Holdings stock appears to be undervalued.
The current stock price of 円102.00 is trading 45.7% below its estimated GF Value™ of 円187.93.
GuruFocus considers Nano Holdings to be Possible Value Trap.
Key valuation signals for TSE:4571:
EBITDA Margin %: -650.35%
GF Value™: 円187.93 vs. price of 円102.00 (45.7% below fair value)
No single metric tells the full story. See the TSE:4571 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nano Holdings Inc formerly, Nano Mrna Co Ltd is engaged in the research and development of pharmaceuticals using micellar nanoparticle technology. The Group's business is a single segment that involves research and development, manufacturing, and sales of pharmaceuticals and other products, as well as related operations.
43GF Score
Get the complete analysis for TSE:4571
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4571 has been successfully added to your 
